Metabolex is a privately held company founded to discover and develop therapeutics for diabetes. The company’s lead product, MBX-102, is a novel insulin sensitizer currently in Phase I clinical trials. Metabolex’s pipeline includes one product candidate in preclinical development, and three other programs optimizing lead drug candidates, one of which is partnered with Abbott Laboratories. Metabolex’s two drug target discovery programs have produced one of the world’s largest databases of diabetes-expressed genes. One of these programs, in insulin secretion, is partnered with Pfizer, Inc., and the other, in insulin resistance, is partnered with Yamanouchi Pharmaceuticals Co., Ltd.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 04/19/07 | Series D | 32M | Avonmore Developments, Vafer Investment Group, ReCap Holdings, LLC, BootStrapped by Vijay, Triple Point Capital, Notion Capital, NYC Seed, QED Investors, Donovan Group Holdings LLC, TEOK Inc., Ben Horowitz, Othman Laraki, Bill Lee, James Hong, Rogers Ventures, Matt Eldridge, Josh Merchant, Heather Ritchie, Marc Simoncini | Unknown |
People
Diana Petty (VP Human Resources)
Patrick O’Mara (VP Business Development)
Paul Quinlan (General Counsel)
Thomas Gustafson (VP Biology)
Charles McWherter (SVP Research & Preclinical Development)
News
Metabolex takes $8.6M to treat diabetes
November 9, 2009 4:49 pm
Metabolex, maker of treatments for Type 2 diabetes, has raised $8.6 million in a fifth round of funding to fund… Continue reading ⟩
Metabolex raises $32 million for metabolic disease treatment
April 20, 2007 11:30 am
Hayward, Calif.’s Metabolex, a biotech company developing treatments for diabetes and related metabolic disorders, said it has raised $32 million… Continue reading ⟩
Metabolex raises $10 million
August 31, 2006 12:42 am
Metabolex, a Hayward, Calif.-based drug company focused on diabetes and related metabolic diseases, has raised $10 million in Series C-1… Continue reading ⟩